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  Bifidobacterium species have been used in the production of 
functional foods based on their well-known beneficial effects on 
intestinal health. B. bifidum BGN4 is a commercialized probiotic 
strain with proven evidence in clinical trials but still lacks a 
DNA-based identification method. This study aimed to develop a 
specific polymerase chain reaction (PCR) primer set for strain 
specific identification of B. bifidum BGN4 using whole genome 
sequences and applied research. Consequently, a primer set 
targeting 200 bp was developed. The developed primer was 
applied to detect and quantify B. bifidum BGN4 strain in the 
fecal sample after feeding ICR mouse and bio-distribution of this 
- ii -
strain was analyzed at each position of the intestinal tract. 
Strong viability of B. bifidum BGN4 was identified by analysis of 
gastrointestinal contents and mouse fecal samples. Also, intake 
of B. bifidum BGN4 promoted the quantity and viability of 
Bifidobacterium genus in GI tract. This study revealed that the 
administration of B. bifidum BGN4 promoted the colonization of 
not only B. bifidum BGN4 but also the other Bifidobacterium 
strains.
Key words : Bifidobacterium bifidum BGN4, polymerase chain 
reaction, colonization
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1. Introduction
The health promoting effects of various probiotics have been 
studied and several lactic acid bacteria and bifidobacteria are 
used in probiotic products to meet its growing demands. The 
intake of probiotics has been proved to modulate the composition 
of the intestinal microflora, alleviate allergic symptoms and 
irritable bowel disease [1, 2]. Furthermore, the effects of 
probiotics on the promotion of immunologic functions and 
improvement of lactose tolerance are reported in many previous 
studies [3, 4]. 
Bifidobacterium bifidum BGN4 (BGN4) is a strain that had 
been isolated from the fecal sample of a healthy breast-fed 
infant [5]. This strain inhibits the growth of several cancer cell 
lines and lowers the production of allergy-related cytokines 
from mouse cells [6, 7]. Furthermore, BGN4 showed the highest 
adhesion capacity among various Bifidobacterium species, which 
is a desirable property for its colonization in gastrointestinal (GI) 
tracts [8]. The ability to adhere to intestinal cells may play a 
critical role on the colonization and the expression of the 
probiotic properties of the administered strains in a host 
intestine [11]. In double-blind, randomized placebo-controlled 
- 2 -
human trials the products containing BGN4 significantly lowered 
the prevalence of atopic dermatitis in infants and also 
significantly lowered the pain scores and increased the bowel 
movement comfortably in irritable bowel syndrome patients [9, 
10]. To understand more deeply, understanding on how the 
intestinal colonization can contribute to clinical results of the 
probiotics is needed.  Although various researches investigated 
the survival capacity and adhesion of probiotics using in cell 
experiments, in vivo experiments are far more instructive. 
However, there were no appropriate methods for analysing the 
viability of bacteria in mouse model.
Recently, many studies have been researched about probiotic 
bacteria in strain levels and the necessity of strain specific 
detection methods are increasing [11-17]. However 
culture-based methods can not be used to identify the 
administered bacteria at a strain level and there are many 
drawbacks such as similarity in physiological properties [18]. 
Random amplified polymorphic DNA polymerase chain reaction 
(RAPD PCR), phage related sequence analysis, multiplex PCR 
and DNA sequence homology based method, such as KEGG also 
employed specific identification of a certain probiotic strains [12, 
15, 19]. Among them, RAPD PCR has been widely used to 
identify bacteria at a strain level. However, this method requires 
a large number of bacterial cultures for analysis. Additionally, 
reproducibility was quite low and the detection failure of RAPD 
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method was reported [13, 18]. The aim of the present study 
was to establish a new rapid and accurate method for 
strain-specific detection using NCBI genome sequence 
comparison. 
Furthermore it has been demonstrated that fluorescence in situ 
hybridization (FISH) method has been a tool for the analysis of 
bacterial ecosystem analysis [20]. However it is unsuitable for 
the quantitative analysis of bacteria [1]. Therefore the present 
study was conducted using quantitative real time PCR (qPCR) for 
the analysis of intestinal microflora. 
Although various health promoting effects of BGN4 have been 
reported, the change of intestinal microflora, retention time and 
distribution of GI tracts after the administration of this strain 
have not been fully assessed. For selection and efficacy 
evaluation of probiotic strains, it is necessary to know their 
bio-distribution. Therefore, we tried develop strain specific 
detection and quantification method for BGN4 and applied this 
method to identify the retention time and bio-distribution of 
BGN4 in fecal samples after administration of this strain using 
mouse model. Finally, we also observed the effect of the 
administration of BGN4 on the composition of microbial flora in 
fecal samples after daily administration.
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2. Materials and methods
 2.1. Microorganism and culture conditions
The bacterial strains used in this work are listed in Table 1. 
They were obtained from the Korean Collection for Type 
Cultures (KCTC, Daejeon, Korea) and Food Microbiology Lab., 
Department of Food and Nutrition in Seoul National University 
(Seoul, Korea). 
The experimental bacterial strains were grown in 
de-Mann-Rogosa-Sharpe (MRS) medium supplemented with 
0.05% (w/v) L-cysteine·HCl (Sigma-Aldrich Co., LLC., USA) 
under anaerobic conditions at 37℃ for 18 h.
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No. Bacterial strains
1 Bifidobacterium bifidum BGN4
2 B. bifidum KCTC 3202
3 B. bifidum KCTC 3418
4 B. bifidum KCTC 3440
5 B. longum RD01
6 B. longum RD03
7 B. longum RD47
8 B. longum RD65
9 B. longum RD72
10 B. longum BORI
11 B. adolescentis KCTC 3567
12 B. angulatum KCTC 3236
13 B. animalis KCTC 3219
14 B. breve KCTC 3419
15 B. infantis KCTC 3249
16 B. catenulatum KCTC 3221
17 B. thermophilum KCCM 12097
18 B. pseudocatenulatum G4 KCTC 3223
19 Lactobacillus acidophilus KCTC 3164
20 L. acidophilus KCTC 3145
21 L. plantarum KFRI 708
22 L. rhamnosus KCTC 3237
23 L. casei KFRI 699
24 L. cremoris ATCC 19257
25 L. bulgaricus KCTC 3186
26 L. brevis GABA 100
27 Lactococcus lactis subsp. lactis KCTC 2013
28 Enterococcus faecium KCTC 13225
29 E. faecalis KCTC 2012
30 Streptococcus salivarius subsp. thermohilus   KCTC 3779
Table 1. Bacterial strains used in this study
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 2.2. Strain-specific primer design
A whole genome sequence of BGN4 was manually checked for 
sequence homologue by using National Center for Biotechnology 
Information (NCBI) nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn).
A strain specific primer set was designed using Primer BLAST 
from the NCBI Website 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). The "PCR 
product size” was set to between 80 bp and 200 bp for real 
time PCR and "Database" and "Organism" were set as "nr" and 
"bacteria" respectively. Furthermore, Primer BLAST was used to 
confirm that the primers were complimentary with the target 
sequence but not with other strains. Primer dimers and 
mismatches were checked and primers were synthesized by 
Bionics (Seoul, Korea).
The specificity of primer set was monitored by conventional 
PCR using genomic DNA from 18 Bifidobacterium strains 
including 3 Bifidobacterium bifidum strains and other 12 
reference strains.
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 2.3. DNA extraction 
Genomic DNA of pure culture bacteria (1 ml) was extracted 
using MG™ Cell SV (Doctor Protein, Korea). Extraction was 
performed according to the manufacturer's instructions and the 
total bacterial DNA was eluted with 200 ㎕ of sterile water. 
DNA extracts were aliquoted and stored at -20℃. 
The fecal samples (200mg) of each group were used for DNA 
extraction. DNA from stools and contents of GI tracts except 
stomach sample were extracted according to modified QIAamp 
DNA Stool Mini Kit (Qiagen, West Sussex, UK) protocols to 
improve the yield of the DNA extraction. The optimized condition 
was selected after conducting DNA extraction under the various 
conditions (Table 2). The lysis temperature was increased to 
100℃ and 1 ml lysozyme with TE buffer (50 mg/ml) was added 
before sonication for 4 min (50/60 Hz, 230V, 40 Amps; Qsonica, 
Newtown, CT. U.S.A). Contents of stomach were diluted 1/10 
using 0.9% (w/v) saline and then used for the extraction of 
genomic DNA using MG™ Cell SV (Doctor Protein, Korea). 
Extraction was performed according to the protocols. 
When the data were analyzed, the dilution rate was multiplied. 
DNA samples were stored at -20℃ until further processing.
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Table 2. The optimized conditions for detecting BGN4




1 ASLb 95 5 34.26
2 ASL 95 10 31.98
3 ASL 95 30 NDc
4 ASL 100 5 29.43
5 ASL 100 10 32.97
6 Lysozyme (50 mg/ml)d 37 30 20.63
7








Lysozyme (50 mg/ml) 37 30
22.56
ASL 95 10
10 Lysozyme (50 mg/ml) 37 45 21.95
11











14 Sonication with PBS 1 ml - - 20.82
15 Sonication with ASL 1 ml - - 23.42
aThe   values of each condition were determined by real time PCR. 
BGN4-free feces were spiked with 9 log CFU/ml BGN4 suspension. DNA of 
each sample was extracted following the modified methods.
bASL means buffer ASL which is a lysis buffer of QIAamp DNA Stool Mini Kit 
(Qiagen, West Sussex, UK).
cND: No detection
dThe supplementary lysozyme digestion step was added.
eSonication conditions : Amp 38 %, 4 min, pulse 1 s
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 2.4. Standard curves
  2.4.1. Pure culture standard curve
To construct the pure culture standard curve for the real time 
PCR, DNA was extracted from 1 ml of BGN4 suspension (9 log 
CFU/ml). The standard curve was prepared by serial tenfold 
dilution of this DNA extract. The exact number of BGN4 
(CFU/ml) in the standards was determined by spreading on MRS 
agar plates. The plates were incubated anaerobically for 24 h at 
37℃. 
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2.4.2. Feces-based standard curve
For the feces-based standard, precise amounts of BGN4 
dilutions were spiked to feces. The 200 mg of feces used for 
the preparation of the standard were from mice feces free of 
BGN4. BGN4-free feces were spiked with BGN4 suspension 
from 2 log CFU/ml to 9 log CFU/ml. DNA from these mixtures 
was extracted for the feces-based standard curve. The exact 
number of added BGN4 (CFU/ml) was determined by the same 
method as for the pure culture standard.
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 2.5. Experimental animals
All animal study designs and procedures were approved by the 
local animal ethics committee at the Seoul National University 
(approval number: SNU-160426-6-1). Also animals were 
maintained and treated as a guideline of Institute of Laboratory 
Animal Resource (Seoul National University, Seoul, Korea). 
Five-week-old male ICR mice (n=89, Central Lab. Animal 
Inc., Seoul, Korea) were used in the current study. The animals 
were maintained in a temperature controlled environment (22±
2℃) with relative humidity of 50±10% and the light was 
maintained on a 12 h light/dark cycle. All animals were 
acclimatized for a week prior to being randomly assigned into 
their respective treatment groups based on their body weight. 
They were fed a commercial diet, AIN-93G (TD. 94045, Harlan 
Teklad) and tap water ad libitum in this period.
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 2.6. Lyophillization of bacteria
Freeze-dried BGN4 cells were provided from Bifido Inc., 
Hongcheon, Gangwon 250-804, Korea. 
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 2.7. In vivo study design and sample collection
  2.7.1. Retention of BGN4 in mouse gut and intestinal 
microflora analysis
   2.7.1.1. Study design
Live cell gavage (LG) group mice (n=7) were daily ingested 
for 1 week with 0.2 ml of 0.9% (w/v) saline containing 0.01 g 
of 12 log CFU/g of lyophillized BGN4 cells. Dead cell gavage 
(DG) group mice (n=7) were ingested with dead BGN4 cells 
which were treated by heating at 70℃ with air exposure for 
48h. In addition, 7 mice were fed the same amount of BGN4 
cells mixed with the AIN-93G commercial diet (MP group). 
Mice were daily fed lyophillized BGN4 cells with 5 g of 
powdered AIN-93G for 1 week. Control group mice (n=7) of 
each treatment were orally administered daily with equal volume 
of saline alone or consumed only powdered AIN-93G. 
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   2.7.1.2. Sample collection
To study intestinal retention time of BGN4 and its effects on 
gut microbiota, fecal samples of each group were collected for 7 
days post successive administration for 7 days. The fecal 
samples (200 mg) were used for DNA extraction as described 
above and aliquots of DNA were used in quantification. To 
analyze the effects of BGN4 colonization on the dominant 
microbial composition, fecal levels of total bacteria, Lactobacillus 
and Bifidobacterium were quantified. The number of these 
bacteria was compared between control and BGN4-administered 
mice.
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  2.7.2. Bio-distribution of BGN4 in mouse GI tracts
   2.7.2.1. Study design
To study bio-distribution of BGN4 in the GI tract axis, 63 
healthy mice were fed with a single dose of 0.2 ml of 0.9% 
(w/v) saline containing 0.01 g of 12 log CFU/g of lyophillized 
BGN4 cells by gavage. Mice were sacrificed by CO2 inhalation 
followed by cervical dislocation at 3, 6, 9, 12, 15, 18, 21, 24 h 
post inoculation (n=6-7 mice per time point). 
- 16 -
   2.7.2.2. Sample collection
The samples of stomach, small intestine, cecum, and large 
intestine were excised and contents of each time point 
(approximately 0.1-0.5 g) were immediately weighed for 
conversion followed by quantification. Samples were collected 
separately and stored at -70℃ until further processing. Also, 
fecal samples of each time point were collected for comparing 
the amount of BGN4.
- 17 -
 2.8. Quantitative assay
The concentration of BGN4 in each sample was calculated by 
comparing the threshold cycle () of the sample with that of 
the standard curve according to the instrument manual [14]. The 
concentration of total bacteria, Lactobacillus and Bifidobacterium 
were calculated using relative quantification method of real time 
PCR because dilution factors were different between protocols of 
DNA extraction from pure cultures and from feces. The 
oligonucleotide primers and PCR conditions used for the 
assessment of the amount of BGN4, total bacteria, Lactobacillus 
and Bifidobacterium are listed in Table 3. For real time PCR, 
SYBR Green qPCR mix (2X) (Takara, Japan) was used and the 
samples were amplified by Thermal Cycler Dice Real Time 
System Single (Takara, Japan).
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60 No 40 341  [22]
R-Lac 
5'-CACCGCTACACATGGAG-3'
Table 3. Primer sequences used in this study
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3. Statistical analysis
Data are expressed as mean ± standard deviation. 
Time-dependent BGN4 changes in the feces and contents of the 
GI tracts after treatments were analyzed using SPSS ver 22.0 
software (SPSS Inc.), which were subjected to a one-way 
analysis of variance (ANOVA) followed by Duncan’s multiple 
range test. Within given region, differences between two groups 
were determined with the student’s t-test. P values of <0.05 
were classified as statistically significant. 
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4. Results
 4.1. Search for potential BGN4 specific sequence and 
primers
When the whole genome sequence data was compared with 
those of various Bifidobacterium strains, a 671bp, including 
Xenobiotic Response Element (XRE) type transcriptional 
regulator gene, was highly specific to BGN4 (GenBank accession 
No. NC_017999, 1392770-1393440). The primer set for strain 
specific detection was designed targeting this sequence. A final 
product size of this primer set was 200 bp which was an 
appropriate size for real time PCR　analysis. Selected primer set 
was confirmed to be complimentary with the target sequence but 
not with the other strains. In addition, we checked for 
mismatches and dimers of the primers. 
Specificity test for this primer set by conventional PCR using 
30 reference strains proved that a single band of 200 bp was 
obtained only from BGN4 DNA (Fig. 1). Furthermore, 
florescence intensities were positive only for BGN4 in real time 
PCR analysis. In silico PCR amplification 
(http://insilico.ehu.es/PCR/) against all reported Bifidobacterium 
genomes also showed no predicted amplicon.
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Fig. 1 Conventional PCR using BGN4 specific primer sets
Lane 1-32: BGN4, KCTC 3202, 3418, 3440, B. longum RD01, RD03, 
RD47, RD65, RD72, BORI, B. adolescentis KCTC 3567, B. angulatum 
KCTC 3236, B. animalis KCTC 3219, B. breve KCTC 3419, B. infantis 
KCTC 3249, B. catenulatum KCTC 3221, B. thermophilum KCCM 
12097, B. pseudocatenulatum G4 KCTC 3223, Lactobacillus acidophilus 
KCTC 3164, KCTC 3145, L. plantarum KFRI 708, L. rhamnosus KCTC 
3237, L. casei KFRI 699, L. cremoris ATCC 19257, L. bulgaricus 
KCTC 3186, L. brevis GABA 100, Lactococcus lactis subsp. lactis 
KCTC 2013, Enterococcus faecium KCTC 13225, E. faecalis KCTC 
2012, Streptococcus salivarius subsp. thermohilus KCTC 3779, dimer 
and BGN4 respectively. 
M : 3,000bp size marker.
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 4.2. Standard curves and detection limits
Standard curves were assembled by plotting cycle threshold 
() versus equivalent log cell numbers (Fig. 2). The PCR 
efficiencies of each standard, determined by the slope of the 
standard curves, were calculated based on the equation [23]. 
Amplification efficiencies E were approximately 99% for each 
standard. Based on qPCR results, the detection limit of pure 
culture standard was 2 log CFU/ml. When BGN4 were added to 
the fecal samples at concentration of 3-9 log CFU/g, detection 
limit was 5 log CFU/g feces.
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Fig. 2 Standard curves and detection limits 
(A) Standard curve obtained from serial dilution of BGN4 
genomic DNA, (B) Standard curve obtained from fecal-based 
standard spiked with serial dilution of BGN4. Each datum dot 
represents the average cell count from triplet. Error bars 
indicate standard deviations.
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 4.3. Retention of BGN4 in mouse gut 
To estimate the retention of BGN4 in mouse gut, the amount 
of BGN4 in the fecal samples were quantified following 7 days 
(Fig. 3). The BGN4 cell numbers were below the detection limit 
in every sample prior to administration. The maximum cell count 
was 10.06 (±0.46) log CFU/g and 10.19 (±0.31) log CFU/g at 
day 1 (24 h post administration) for each group. Detected cell 
counts decreased continuously and reached to 5.23 (±0.35) log 
CFU/g and 6.21 (±0.58) log CFU/g at day 7, respectively. 
The cell counts of MP group were significantly higher than 
that of LG group at every time points, except for the 1st day.  
The difference between the two experimental groups was getting 
widen from day 2 to day 7 (Fig. 3). 
BGN4 cell counts in feces of live cell gavage group (LG) were 
higher than dead cell treatment group (DG) in general. DG group 
and LG group showed significant differences at day 2, day 3 and 
day 4 (Fig. 4). 
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Fig. 3 Retention time and cell counts in feces
Fecal samples of each group were analyzed using real time PCR and 
target cell count was quantified. Each datum dot represents the 
average cell count from 7 rats. Error bars indicate standard deviations. 
Student’s t test was used to determine the difference between two 
groups. * P< 0.05, ** P< 0.01.
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Fig. 4 Retention time and cell counts of BGN4 after the 
administration of live or dead cells
Fecal samples of each group were analyzed using real time PCR and 
target cell count was quantified. Each datum dot represents the 
average cell count from 7 rats. Error bars indicate standard deviations. 
Student’s t test was used to determine the difference between two 
groups. * P< 0.05.
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 4.4. Cell counts comparison between single serving 
group and successive ingestion group
In the single serving group, mice were ingested a single dose 
of 0.2 ml of 0.9% (w/v) saline containing 0.01 g of 12 log 
CFU/g of lyophilized BGN4 cells. In a successive oral 
administration group, they had the same amount of BGN4 cells 
for 7 days. 
The number of BGN4 in the feces of mice ingested a single 
serving was confirmed to be 5.58 (±0.47) log CFU/g at 3 h and 
reached maximum of 10.27 (±0.08) log CFU/g at 9 h. Cell 
numbers subsequently decreased to 5.35 (±1.25) log CFU/g at 
24 h. On the other hand, the number of BGN4 in the feces of 
mice ingested for 7 days was confirmed as 7.75 (±0.6) log 
CFU/g at 3 h and reached maximum of 10.37 (±0.02) log CFU/g 
at 12 h. At last, 7.52 (±0.35) log CFU/g cell number was 
detected at 24 h.
There was no significant difference between two groups at 6, 
9, and 21 h post administration. However, there were significant 
differences between two groups at 3, 12, 15, 18 and 24 h post 
administration (P< 0.05 at 18 h and P< 0.01 at 3, 12, 15 and 24 
h). At 27 h, 5.68 (±0.88) log CFU/g was detected only in the 
successive administration group. (Fig. 5).
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Fig. 5 Cell counts comparison between the single serving group 
and the successive ingestion group
▲ : a group administered for 7 days, ● : a group administered single 
dose. Fecal samples of each group were analyzed using real time PCR 
and target cell count was quantified. Each datum dot represents the 
average cell count from 7 rats. Error bars indicate standard deviations. 
Student’s t test was used to determine the difference between two 
groups. * P< 0.05, ** P< 0.01.
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 4.5. The analysis of the composition of fecal 
microflora
Total bacteria and Lactobacillus was not significantly different 
between the control and the administered group at every time 
points. On the other hand, the number of Bifidobacterium was 
increased considerably in the LG group (Fig. 6). The fecal 
Bifidobacterium level was under the detection limit in the control 
group and in all groups prior to administration. However, after 
administration of BGN4 (LG-BGN4), Bifidobacterium cell counts 
were higher than 10 log CFU/g at every time points except for 
day 2 (9.42±0.57 CFU/g). 
Though the cell counts of BGN4 decreased gradually after 
probiotic treatment, Bifidobacterium still maintained at a high 
level until 7 days post administration in LG group. In case of DG 
group, BGN4 cell count tended to decline as shown in LG group. 
However, no significant increase of Bifidobacterium was detected 
in DG group (Fig. 6).
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Fig. 6 Fecal microbial composition analysis 
Absolute and relative qPCR quantification were conducted to analyze 
dominant and subdominant microbes in fecal samples. Each datum dot 
represents the average cell count from 7 rats. Error bars indicate 
standard deviations.
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 4.6. The bio-distribution of BGN4 in mouse GI   
tracts
The bio-distribution of ingested BGN4 in the longitudinal gut 
axis such as stomach, small intestine, cecum, large intestine and 
feces are shown in Fig. 7. The BGN4 numbers were below 
detection limit in every sample prior to administration of BGN4.
In stomach contents (Fig. 7A), the cell counts of BGN4 were 
the highest at 3 h after the gavage conducted, which was 4.02 
(±1.46) log CFU/g. 
In the small intestine (Fig. 7B), the cell counts were the 
highest at 9 h after gavage (8.66±0.54 log CFU/g). 
Interestingly, BGN4 cell numbers were under the detection limit 
at 21 h and 24 h in the small intestine after gavage. 
From 3 h after gavage to 21 h, BGN4 cell counts in cecum 
were maintained at a high level, with a cell count of ≥ 7 log 
CFU/g. At 24 h, 5.95 (±0.91) log CFU/g was detected (Fig. 
7C). 
The maximum cell count in large intestine was 10.15 (±0.38) 
log CFU/g at 9 h post gavage. Like fecal samples, BGN4 cell 
counts in the large intestine luminal contents continuously 
decreased until 24 h with 4.96 (±1.31) log CFU/g (Fig. 7D). 
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In the fecal samples, BGN4 cell counts were sharply increased 
from 5.58 (±0.47) log CFU/g at 3 h to 10.22 (±0.08) log 
CFU/g with a maximum level at 9 h (Fig. 7E).
- 33 -
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Fig. 7 The bio-distribution of BGN4 in mouse GI tracts
Each datum dot means the average cell count (log cell counts per gram 
intestinal contents or feces) from 7 rats. Error bars indicate standard 
deviations. Statistical significance was determined by the Duncan’s 




BGN4 has been reported as promising probiotic bacteria with 
many positive research results. To achieve the expected effects, 
BGN4 has to survive in a harsh GI tract environment. The 
survival capacity, the distribution, and the passage tendency of 
BGN4 must be verified at the strain level because various 
probiotic characteristics are strain-dependent [24]. Therefore 
the survival capacity in the GI tract and the luminal colonization 
of BGN4 warrants a thorough investigation. Furthermore, there 
were no observations on how the intake of live or dead BGN4 
differently influences the balance of the mouse intestinal 
microflora. In this study, we observed the alteration of the 
intestinal microflora composition after administration of BGN4 for 
7 days using real time PCR. 
However, there was no applicable method for detecting 
bacterial cell counts of BGN4 for quantification. Selective medium 
for the differentiation of BGN4 from other Bifidobacterium strains 
was absent [25]. Therefore we established a strain specific 
detection method based on DNA sequence to quantify target 
bacteria in feces and GI tract contents by using real time PCR. 
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The detection limits of our standard curves were quite similar to 
those in previously reported real time PCR assay for species or 
strain specific detection [12,14]. 
Next, we analyzed how the different dietary methods could 
affect the retention time and viability of BGN4. To our 
knowledge, Bifidobacterium is reported to be less acid resistant 
than Lactobacillus, especially under a gastric juice environment 
[26]. However the acidic environment of the stomach is likely to 
be neutralized by foods. Thus, the ingested probiotic bacteria 
may survive easily in the stomach when consumed together with 
foods [27]. Likewise, the consumption method of the MP group 
in which the BGN4 was mixed with diet might have promoted 
the viability and the colonization of BGN4.
The feeding periods of BGN4 may also be related to the viable 
cells of BGN4 detected in the fecal samples. When the feces of 
successive oral administration for 7 days were compared with a 
single gavage, BGN4 accumulates and colonizes in the gut 
efficiently in the successive administration. Previously, it was 
also shown that oral administration for 7 days could increase cell 
counts at a higher level in feces than the single dose group 
[12]. Moreover, each group has the highest cell counts at 9 h 
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and 12 h after oral administration, which coincides well with the 
physiological transit time of mice [28]. 
Furthermore, the passage and the colonization of BGN4 were 
assessed in the GI tracts and feces after administration. This in 
vivo study is more informative than a simulation study of an 
artificial gastric environment to demonstrate the survival capacity 
of probiotic bacteria [29-32]. In the stomach, there were less 
than 4 log CFU/g cells on average, probably because the 
environment of the stomach is harsh for probiotic bacteria to 
survive or colonize. Interestingly, BGN4 was not observed in the 
small intestine at 21 and 24 h post single administration. The 
bile and the pancreatic enzymes could affect the viability of 
BGN4 in the small intestine. Moreover, the intestinal peristalsis 
play important roles in preventing bacterial colonization in the 
small intestine [33]. As well known, the probiotic 
Bifidobacterium localize preferably in the cecum and the colon 
where is strictly anaerobic. The maximum cell counts of the 
cecum and the large intestine were high in comparison with 
other sessions of GI tracts. According to data obtained, the 
cecum was found to be the principle habitat for Bifidobacterium 
in mice. Cell adhesion and the colonization of BGN4 in the cecum 
and colon may vary depending on various environmental factors 
such as pH, nutrients, and the presence of proteolytic enzymes 
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and lipoteichoic acids in the bacterial cells [8]. At 9 h, BGN4 
cell counts in the stool samples and the large intestine were 
slightly higher than the number originally administered which 
result imply successful colonization and proliferation of BGN4 in 
the mouse GI tracts. It has been shown that bifidobacteria 
survived passage to the large intestine, with 29.7% of ingested 
cells being able to reach the colon [34]. 
Substantiating a health benefit related to the consumption of 
probiotics, one commonly considered parameter is whether a 
specific probiotic strain can have impact on the composition of 
host microflora [35]. According to the previous studies, live 
probiotic cells can modify the gastrointestinal microflora directly, 
whereas the component of dead cells can only exert an 
anti-inflammatory response in the GI tract and act as biological 
response modifiers [36]. In this respect, we monitored the 
change of intestinal microflora after the administration of live or 
dead BGN4. Interestingly, before the administration, we could not 
detect Bifidobacterium in the fecal samples using real time PCR 
because the cell counts were under the detection limit level. 
However, according to the previous studies, Bifidobacterium and 
Lactobacillus were reported to be abundant in mouse fecal 
samples [37, 38]. This discrepancy might have come from the 
difference of mice breeding facilities [39]. In other words, the 
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different mice strains may have different microbial composition in 
their guts. Furthermore, diet composition may differently affect 
gut microflora [40]. 
Surprisingly, microbial composition of mouse fecal samples was 
changed only when the mice administered live BGN4 cells. The 
numerical increase of Bifidobacterium in feces after 
administration was only detected in the LG group although BGN4 
cells decreased time-dependently in both the LG group and the 
DG group. This finding disagrees with the existing study that the 
normal intestinal microbes have a strong resistance against the 
colonization by newly ingested bacteria [41]. Previously, 
probiotic bacteria affected the intestine environment if their 
population reaches a minimum level of 6 log CFU/g to 8 log 
CFU/g [41]. Therefore, the ingestion of 10 log CFU/g BGN4 for 
7 days might have overcome the resistance against the 
colonization of the newly administered bacteria. The intestinal 
microflora of the LG group mice might have been changed by 
the high dose administrations. Since Bifidobacterium reduce the 
intestinal endotoxin level and enhance the mucosal barrier 
function, this result could have a positive meaning [42]. 
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6. Conclusion
In this research, the strain specific detection and quantification 
method for BGN4 was established through comparative genomics. 
Using this method, the retention time, the retention amount, the 
bio-distribution, and changes of intestinal microflora after 
adminstration were identified. In summary, this study would 
demonstrate that probiotic properties of BGN4 can be promising, 
as it survived in mouse GI tracts for 7 days. Furthermore, BGN4 
could positively change the composition of microflora by 
increasing the number of Bifidobacterium. To broaden our 
knowledge about probiotic properties of BGN4, investigations are 
needed to identify the biological mechanism of interactions 
between BGN4 and gut microflora. 
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Bifidobacterium은 장내 환경에 유익한 영향을 주어 기능성 식품으로 
자주 이용되어왔다. 상업 균 주인 Bifidobacterium bifidum BGN4의 경
우 다양한 임상 연구를 통하여 그 효과가 입증되었으나 유전체를 이용한 
검출 방법이 부재하여 균 주를 특이적으로 검출해 낼 수 있는 방법이 미
비하였다. 따라서 이번 연구를 통해 B. bifidum BGN4의 유천체를 다른 
유산균들과 비교하여 특이적으로 검출할 수 있는 방법을 수립하였다. 프
라이머 세트는 real time PCR 분석에 이용될 수 있도록 최종 증폭 산
물의 사이즈를 200 bp로 하여 설계되었으며, 이는 ICR mouse의 분변
과 장관 내 내용물에서 해당 균주를 빠르고 정확하게 검출 해 내는 것에 
사용되었다. 분석 결과 B. bifidum BGN4 의 경우 장관내의 생존능이 
비교적 강한 것으로 확인되었다. 또한 B. bifidum BGN4의 장관 내 흐
름을 가시적으로 확인하였으며, 해당 균주를 섭취한 후의 변속 균 총을 
확인 하였다. 그 결과 생 균 상태의 B. bifidum BGN4를 섭취할 경우 
B. bifidum BGN4뿐만 아니라 장관 내 Bifidobacterium의 우점화를 크
게 향상 시키는 긍정적인 효과를 확인할 수 있었다.
주요어 : Bifidobacterium bifidum BGN4, 중합효소연쇄반응, 우점화
학  번 : 2015-21709
